Background: There are in vitro, animal and phase 2 studies suggesting that statins may be beneficial in the acute respiratory distress syndrome (ARDS). This study tested the hypothesis that treatment with simvastatin would improve clinical outcomes in patients with ARDS. Methods: In this multicentre, allocation concealed, double-blind clinical trial, patients with an onset of ARDS within the previous 48 hours were randomized in a 1:1 ratio to receive enteral simvastatin 80mg or placebo once daily for a maximum of 28 days. The primary outcome was the number of ventilator-free days to day 28. Secondary outcomes included number of non-pulmonary organ failure free days to day 28, mortality at 28 days and safety. Results: The study recruited 540 patients with 259 patients allocated to simvastatin and 281 patients to placebo. The groups were well matched with respect to demographic and baseline physiological variables. There was no significant difference between study groups in mean (± SD) ventilator-free days (12.6±9.9 with simvastatin and 11.5±10.4 with placebo, P = 0.21), non-pulmonary organ failure free days (19.4±11.1 with simvastatin and 17.8±11.7 with placebo, P = 0.11) or in 28-day mortality (22.0% with simvastatin and 26.8% with placebo, P = 0.23). There was no difference in the incidence of severe adverse events between the groups. Conclusions: Simvastatin therapy, while safe and with minimal adverse effects, did not improve clinical outcomes in patients with ARDS.
Methods: In this multicentre, allocation concealed, double-blind clinical trial, patients with an onset of ARDS within the previous 48 hours were randomized in a 1:1 ratio to receive enteral simvastatin 80mg or placebo once daily for a maximum of 28 days. The primary outcome was the number of ventilator-free days to day 28. Secondary outcomes included number of non-pulmonary organ failure free days to day 28, mortality at 28 days and safety.
Results: The study recruited 540 patients with 259 patients allocated to simvastatin and 281 patients to placebo. The groups were well matched with respect to demographic and baseline physiological variables. There was no significant difference between study groups in mean (± SD) ventilator-free days (12.6±9.9 with simvastatin and 11.5±10.4 with placebo, P = 0.21), non-pulmonary organ failure free days (19.4±11.1 with simvastatin and 17.8±11.7 with placebo, P = 0.11) or in 28-day mortality (22.0% with simvastatin and 26.8% with placebo, P = 0.23). There was no difference in the incidence of severe adverse events between the groups. . In addition in a small single centre, randomized, placebo-controlled study simvastatin improved non-pulmonary organ dysfunction and was safe written informed consent. Simvastatin was purchased for use in the study.
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Study medication
Patients were randomized in a 1:1 ratio using an automated centralised 24-hour randomization service. Randomization was by permuted block stratified by site and by vasopressor requirement.
Patients received once daily simvastatin 80mg or identical placebo tablets enterally for up to 28 days. The first dose of study drug was administered as soon as possible, ideally within 4 hours of randomization, and subsequent doses were given each morning starting on the following calendar day.
Study drug was continued until day 28, discharge from critical care, death or discontinuation of active medical treatment, development of a clinical condition requiring immediate treatment with a statin or withdrawal of the patient from the study. The study drug was stopped on safety grounds if the attending clinician determined that this was , but no specific ventilator management scheme was promulgated. All other treatment was determined by the patients' physicians.
Outcome measures
The primary outcome measure was ventilator-free days (VFDs) to day 28 defined as the number of days from the time of initiating unassisted breathing, to day 28 after randomization 6 . A detailed definition of VFDs is provided in the study protocol available at NEJM.org. Secondary outcomes included change in oxygenation index (OI) and sequential organ failure assessment (SOFA) score 10 up to day 28, number of non-pulmonary organ failure free days (OFFDs) to day 28, all cause mortality 28 days post randomization, mortality at discharge from critical care and from hospital, and safety.
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Statistical analysis
Sample size assumptions were based on previously published data 5, 9 . Assuming a mean (SD) for VFDs of 12.7 (10.6) days, a sample size of 524 subjects would need to be enrolled to have 80% power at a two-tailed significance level of 0.05 to detect a mean difference of 2.6 VFDs. Data from the PAC-Man trial were used to estimate a dropout rate of 3% 11 and therefore the study required a total of 540 patients.
Analyses were on an intention-to-treat basis. As VFDs and non-pulmonary OFFDs are known to have a bimodal distribution, the groups were initially analysed by t-test with difference in means and 95% confidence intervals (CI) presented. A secondary analysis of these outcome measures involving a bootstrapped t-test was also conducted to support the findings of the t-tests as detailed in the statistical analysis plan available at NEJM.org. For binary outcome measures, risk ratios and associated 95% CI were calculated. Time-to-event data are presented using Kaplan-Meier plots. The hazard ratios (HR) were calculated and the log rank chi-square test used to compare the survival function of treatment arms. All
HRs are presented with a 2-sided 95% CI. All P values are 2-sided. To assess whether treatment was more or less effective in pre-defined subgroups, analyses were undertaken to analyse whether the treatment effect was modified by age, vasopressor requirement, presence of sepsis and baseline CRP. Subgroup analyses used a statistical test for interaction and are reported using 99% CI.
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The baseline characteristics of the patients at randomization were similar in the two study groups except for a small but statistically significant lower PaO 2 /FIO 2 ratio in the simvastatin group (Table 1) . The main causes of ARDS were pneumonia and sepsis. There was no significant difference in tidal volume at day 3; mean difference (95% CI) was 0.1 (-0.6 to 0.7) ml/kg predicted body weight (P = 0.89).
Patients received study drug for a mean (±SD) of 10.2 ± 7.1 days in the simvastatin group and 11 ± 7.9 days in the placebo group (P = 0.23). The commonest reasons for discontinuation of study drug were discharge from critical care, death and a study drug related adverse event. Five patients allocated to simvastatin and 3 patients allocated to placebo received treatment with non-trial statins (Table S1 in the Supplementary Appendix).
Outcomes
The number of ventilator-free days was not significantly different between the study groups (12.6±9.9 with simvastatin and 11.5±10.4 with placebo, mean difference (95% CI) of 1.1 (-0.6 to 2.8); P = 0.21). There was no significant difference in the number of ventilator-free There were no significant differences in the change in oxygenation index (Tables S2 and S3 in the Supplementary Appendix) or SOFA score from baseline between the groups (Table   S2 in the Supplementary Appendix). There was no significant difference in the number of non-pulmonary organ failure free days or 28-day mortality. Mortality at critical care discharge or hospital discharge was also not significantly different ( Table 2) There was no significant difference in the probability of breathing without assistance to day 28 or survival ( Fig. 2) .
Subgroup analyses did not suggest that the effects of simvastatin were modified by any of the variables investigated. There was no statistically significant interaction between treatment and age (P = 0.62), vasopressor requirement (P = 0.17), presence of sepsis (P = 0.50) and baseline C-reactive protein (CRP) (P = 0.77) ( Table S4 in the Supplementary Appendix).
There were no differences in plasma CRP between the simvastatin and placebo groups at baseline, at day 3 or day 7 or in the change in the CRP from baseline (Tables S5 and S6 in the Supplementary Appendix).
Overall adverse events related to study drug were significantly more common in the simvastatin group. The majority were related to elevated creatine kinase and hepatic transaminases. Serious adverse events (SAEs) (other than those reported as trial outcomes e.g. death) were similar in both groups (Table S7 in the Supplementary Appendix). There was no difference in the proportion of patients with non-pulmonary organ dysfunction as 3 and observational studies 13, 14 which supported using a higher dose. While we did not measure simvastatin concentrations, it is likely that an adequate simvastatin concentration was achieved for several reasons.
Prior studies in the critically ill indicate that simvastatin 80mg daily produces systemic drug concentrations that are in the high therapeutic range Although there was a higher incidence of adverse events related to simvastatin, the number of serious adverse events were similar in both groups. The finding that the proportion of patients with no organ dysfunction as measured by SOFA score over the course of the study was similar in both groups is reassuring. The absence of serious harm with simvastatin in this population provides reassurance in regard to the safety of statins in patients with ARDS used for other proven indications.
We recruited a heterogeneous cohort of patients with ARDS due to any etiology to ensure that our findings would be generalisable. Recent data have suggested that it may be possible to identify specific phenotypes within ARDS 17 . Future studies may identify an ARDS subpopulation which might be more responsive to simvastatin. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 were assigned zero ventilator free days. † The results from the bootstrapped t-test also presented.
# Non pulmonary organ failure-free days are defined in the study protocol. Patients who died before day 28 were assigned zero non pulmonary organ failure-free days. Organs were considered failure-free after patients were discharged from the critical care unit. § Risk Ratio and 95% CI.
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